195 related articles for article (PubMed ID: 21811108)
1. The growing role of epidemiology in drug safety regulation.
Hamburg MA
Epidemiology; 2011 Sep; 22(5):622-4. PubMed ID: 21811108
[No Abstract] [Full Text] [Related]
2. Epidemiologic studies, warts and all, are our best chance.
Hernán MA
Epidemiology; 2011 Sep; 22(5):636-7. PubMed ID: 21811112
[No Abstract] [Full Text] [Related]
3. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research.
Madigan D; Ryan P
Epidemiology; 2011 Sep; 22(5):629-31. PubMed ID: 21811110
[No Abstract] [Full Text] [Related]
4. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
5. MedWatch. On lookout for medical product problems.
Ropp KL
FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
[No Abstract] [Full Text] [Related]
6. Drug-safety pilot makes the grade.
Ledford H
Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
[No Abstract] [Full Text] [Related]
7. Research on drug safety and effectiveness using pharmacoepidemiological databases.
Andersen M
J Intern Med; 2014 Jun; 275(6):548-50. PubMed ID: 24635741
[No Abstract] [Full Text] [Related]
8. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
Goldman SA
Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
[No Abstract] [Full Text] [Related]
9. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
10. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?
Faden LB; Milne CP
Food Drug Law J; 2008; 63(3):683-700. PubMed ID: 19031668
[No Abstract] [Full Text] [Related]
11. View from the Nation's Capital. "Off-label" uses of approved drugs: limits on physicians' prescribing behavior.
Appler WD; McMann GL
J Clin Psychopharmacol; 1989 Oct; 9(5):368-70. PubMed ID: 2794099
[No Abstract] [Full Text] [Related]
12. Reform of drug regulation--beyond an independent drug-safety board.
Ray WA; Stein CM
N Engl J Med; 2006 Jan; 354(2):194-201. PubMed ID: 16407517
[No Abstract] [Full Text] [Related]
13. Pediatric post-marketing safety systems in North America: assessment of the current status.
McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
[TBL] [Abstract][Full Text] [Related]
14. ORA's role at FDA headquarters and in the field for product recalls.
Whetstone SN
Food Drug Law J; 1998; 53(3):513-6. PubMed ID: 10346723
[No Abstract] [Full Text] [Related]
15. The impact of FDA reform.
Trunzo J
Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
[TBL] [Abstract][Full Text] [Related]
16. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Zelenay JL
Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
[No Abstract] [Full Text] [Related]
17. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
18. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
Kou Q; Zhao S; Feng G; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
[TBL] [Abstract][Full Text] [Related]
19. FDA tightens its grip on drug regulation.
Coombes R
BMJ; 2007 Feb; 334(7588):290-1. PubMed ID: 17289729
[TBL] [Abstract][Full Text] [Related]
20. Postmarketing follow-up: physicians have key role.
Goldsmith MF
JAMA; 1985 Oct; 254(16):2217. PubMed ID: 4046146
[No Abstract] [Full Text] [Related]
[Next] [New Search]
